Due: March 27, 2024
Enhanced White Paper for FDA approval of an improved oxime in a vial to increase warfighter survivability.
This opportunity requires membership in the MCDC Consortium. This Consortium releases numerous opportunities throughout the year, so even if this one may not be right for you, we strongly encourage you to join the consortium, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.